#National Cancer Institute

RESPOND study will investigate why they disproportionately experience aggressive disease.

In a survey, parents ranked “It can prevent some types of cancer” as the best reason for their children to receive the vaccine.

NExT combines the best of the federal government and the private sector, and it is only getting better with time.

“While these studies represent progress, it is incremental. There’s so much room for improvement.”

Results from two studies showed that more frequent tests did not change the rate of detection of recurrence or death due to cancer.

Biosimilar products can provide additional treatment options and create market competition, potentially lowering the costs of treatment.

As more people survive after cancer treatment, mental fog has become a growing concern.

“These are the best outcomes reported to date in a Children’s Oncology Group trial for children with this cancer,” said the lead author.

Moxetumomab pasudotox “offers an option for patients with relapsed or refractory hairy cell leukemia that avoids additional chemotherapy.”

“There’s been a lot of concern about variants of unknown significance and the confusion and stress they may cause for patients.”

“If we can help clinicians shift their focus to those most at risk, that would be really helpful,” said NCI’s Stefanie Nelson, PhD.

“The very mutations that cause the cancer may prove to be the best targets to treat the cancer.”

Results strengthen the path forward for targeted cancer therapies.

We still don’t have cancer totally figured out, so now is not the time to reduce our efforts in the basic investigation of cancer biology.

Researchers say adopting the treatment “could spare patients a lot of suffering from repeated surgeries and save health care costs.”

Findings shed light on mechanisms that lead to liver cancer and for approaches to treat them.